Compare iShares MSCI China ETF (MCHI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI China ETF trades at $52.53 (market cap $5.94B), while Novo Nordisk A/S trades at $38.6 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 27.8× iShares MSCI China ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Novo Nordisk A/S for 116 Days on average.
| MCHI | NVO | |
|---|---|---|
Market Cap | $5.94B | $165.31B |
Volume | 1,575,471 | 11,432,838 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $63.98 |
52-Week Low | $50.48 | $35.29 |
Typical Hold Time | 63 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.55, up 1.76% today, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights potential trade tensions ahead of the Trump-Xi summit, though corporate profits surged 26% in Q2 according to Zacks Investment Research (2026-09-08).
The outlook remains cautious due to China's macroeconomic pressures and global trade risks. Investment opportunity exists in MCHI's significant discount to historical valuations versus US indices, but risks include potential export controls and protectionism. The ETF's financial sector benefits from China's steepening yield curve, supporting bank and insurance holdings.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
